Yates Jennifer L, Palat David S, Subik M Kristina, Lee William T, McDonough Kathleen A, Conuel Edward
Albany Medical Center, Transfusion Medicine, Albany, NY, United States.
New York State Department of Health, Division of Infectious Diseases, Wadsworth Center, Albany, NY, United States.
Clin Immunol Commun. 2022 Dec;2:57-61. doi: 10.1016/j.clicom.2022.03.001. Epub 2022 Mar 10.
Convalescent plasma (CP) has been the first line of defense against numerous infectious diseases throughout history. The COVID-19 pandemic created a need for a quick, easily accessible, and effective treatment for severe disease and CP was able to meet that immediate need. The utility of CP warrants a better understanding of the pharmacokinetics of CP treatment. Here we present the case of a COVID-19 patient with a genetic deficiency in antibody production who received CP as a part of the treatment regimen. In depth serological analysis revealed a surprising lack of SARS-CoV-2 specific antibodies and reduced serum IgG following CP infusion. Our study highlights plasma dilution and accelerated antibody clearance as potential mechanisms for the variable efficacy of CP therapy.
恢复期血浆（CP）在历史上一直是抵御众多传染病的第一道防线。新冠疫情使得对重症疾病的快速、易于获取且有效的治疗产生了需求，而CP能够满足这一紧迫需求。CP的效用需要我们更好地理解CP治疗的药代动力学。在此，我们呈现一例新冠患者的病例，该患者存在抗体产生的基因缺陷，其接受了CP作为治疗方案的一部分。深入的血清学分析显示，在输注CP后，令人惊讶地缺乏新冠病毒特异性抗体且血清IgG降低。我们的研究强调血浆稀释和抗体清除加速是CP治疗效果不一的潜在机制。
